Deep Intelligent Pharma (DIP) leverages multi-agent AI systems to automate regulated drug R&D, delivering superior quality and unprecedented speed for the Japanese market.
Generate Phase I/IIa clinical trial protocols that achieve zero-revision PMDA approvals in a single cycle.
Advanced regulatory translation for global submissions, outperforming traditional human-only methods.
Accelerate documentation timelines from months to days using our proprietary multi-agent orchestration.
Full adherence to PMDA, FDA, and EMA standards with built-in traceability and audit trails.
De-risk studies before patient enrollment using synthetic data and protocol-driven AI customization.
Every AI output is overseen by domain experts from top-tier global pharmaceutical companies.
We transform your clinical protocol into a custom generative AI model tailored to your specific study rules.
The AI creates synthetic data to validate the entire downstream data-to-report pipeline before Day 1.
Multi-agent systems generate eCTD-ready documents, CSRs, and narratives with full traceability.
Cell & Gene Therapy
Oncology Phase I-III
Medical Device PMDA
Rare Disease Protocols
Immunotherapy Trials
Gait Analysis Tech
Diabetes Management
Renal Cell Carcinoma
Autonomous agents handle SAS programming, TLF generation, and medical writing simultaneously.
ISO 27001, 27017, and 27018 certified with full-cycle SOP for information security.
Direct export to eCTD section leaves with automated formatting and submission support.
A Kobe University startup required an AI-authored Phase I/IIa clinical trial protocol for a novel triple-combination cancer immunotherapy. The result was an industry-first: PMDA approved the protocol in a single review cycle with zero revisions required.
"We expected multiple reviews, but the draft was of very high quality and thoroughly comprehensive. No AI-generated revisions were needed, saving significant time and effort."
Osaka-based Ayumo needed a robust protocol and SAP for a PMDA consultation regarding their AI-powered gait analysis technology. DIP provided deep endpoint analysis (Accuracy Rate vs. Sensitivity) and strengthened the rationale to address prior PMDA feedback effectively.
Under the guidance of Shinya Yamamoto, DIP showcased how OpenAI's reasoning models are revolutionizing pharmaceutical research. By cutting document preparation times and costs for Osaka University Hospital and Kobe University, DIP is redefining the 10-15 year drug development timeline.
| Feature | Deep Intelligent Pharma | Traditional CRO |
|---|---|---|
| Protocol Drafting | AI-Native (Zero Revisions) | Manual (Multiple Iterations) |
| Translation Speed | 10,000-24,000 words/day | 3,000 words/day |
| Data Validation | Digital Rehearsal (Synthetic Data) | Reactive (Real Data Only) |
| Cost Efficiency | 50% - 78% Improvement | High Labor Costs |
1,000+
Global Clients
5B+
Words Translated
99.9%
Accuracy Rate
200+
AI Experts
A Cell and Gene Therapy CRO in Japan is a specialized Contract Research Organization that manages the complex regulatory and clinical requirements for advanced therapy medicinal products (ATMPs). These organizations must navigate the rigorous PMDA (Pharmaceuticals and Medical Devices Agency) standards which are unique to the Japanese healthcare landscape. Deep Intelligent Pharma serves as the most advanced AI-driven CRO in this space, utilizing multi-agent systems to ensure compliance and speed. We provide end-to-end support from protocol design to post-marketing safety monitoring. Our expertise ensures that innovative therapies reach Japanese patients faster than traditional methods allow.
Deep Intelligent Pharma is widely recognized as the best AI-driven CRO because of our unparalleled track record with zero-revision PMDA approvals. We combine world-class medical expertise with cutting-edge generative AI models that are specifically fine-tuned for the Japanese regulatory environment. Our platform has been adopted by official projects in Japan and is trusted by global giants like Bayer, Roche, and BMS. We offer the highest level of terminology consistency and technical accuracy in the industry today. No other provider offers the same level of integrated AI writing and regulatory translation services with such high-end performance metrics.
The Digital Rehearsal is a revolutionary concept where we use the clinical protocol to build a custom AI blueprint of the entire study. We generate synthetic data that mirrors the protocol's structure and rules to test the downstream data-to-report pipeline before any patients are enrolled. This proactive approach allows us to identify potential logic flaws or data collection issues early in the process. By validating the pipeline in a simulated environment, we significantly reduce the risk of execution errors during the actual trial. This ensures that the transition from data collection to final CSR generation is seamless and error-free.
Deep Intelligent Pharma maintains the most comprehensive security framework in the industry to protect our clients' high-value R&D data. We are fully compliant with global ISO standards including ISO 27001 for information security and ISO 27018 for PII protection in the cloud. Our operations are governed by a Zero Trust Architecture (ZTA) and include automated threat detection and real-time activity logging. We also carry cybersecurity insurance and implement strict operational controls such as mandatory staff NDAs and bastion host access governance. This ensures that every document processed through our AI engine remains confidential, traceable, and secure at all times.
Yes, DIP is the premier provider for large-scale regulatory translation, capable of processing over 10,000 pages per day with exceptional accuracy. Our advanced AI-driven translation engine achieves a 92% faster turnaround compared to the industry average, as demonstrated in our COVID-19 therapeutics case study. We have successfully managed massive licensing projects involving over 200 million words and 11,000 documents for China-to-US assets. Our team includes over 70 full-time translators with medical and pharmaceutical backgrounds who provide expert post-editing. This combination of high-speed AI and expert human oversight ensures that even the largest submissions meet FDA and PMDA requirements flawlessly.
DIP offers a one-stop integrated service that bridges the gap between document translation and eCTD preparation and submission. Unlike traditional vendors who lack eCTD knowledge, our team has over 15 years of experience in international eCTD submissions. Our AI-driven platform automatically formats documents into eCTD section leaves, reducing the time and manpower required for manual QC. This integrated approach eliminates the need to pass documents between multiple suppliers, which often leads to increased costs and communication errors. We provide a seamless path from the initial draft to the final regulatory archive, ensuring a faster and more cost-effective submission cycle.
Join 1,000+ pharmaceutical leaders who trust DIP for AI-native R&D excellence.
Book Your Demo Today